首页 >>2014年09期
肠道病毒71型灭活疫苗临床试验的现状及展望
作者:嵇红 毛群颖 王慎玉 朱凤才

摘要:

关键词:

Abstract:

Key words:

发表日期:2014/9

引用本文:

图/表:

  • 10.3760/cma.j.issn.0253-9624.2014.09.017.T001:表1 不同企业研发的EV71灭活疫苗及其各期临床试验研究设计、研究人群、免疫程序和剂量分组;

    10.3760/cma.j.issn.0253-9624.2014.09.017.T001:表1 不同企业研发的EV71灭活疫苗及其各期临床试验研究设计、研究人群、免疫程序和剂量分组;

参考文献:

[1]SchmidtNJ, LennetteEH, HoHH. An apparently new enterovirus isolated from patients with disease of the central nervous system[J]. J Infect Dis, 1974, 129(3):304–309.
[2]OoiMH, WongSC, LewthwaiteP, et al. Clinical features, diagnosis, and management of enterovirus 71[J]. Lancet Neurol, 2010, 9(11):1097–1105.
[3]World Health Organization.Severe complications of hand, foot and mouth disease (HFMD) caused by EV–71 in Cambodia – conclusion of the joint investigation[EB/OL].2012–07–13.http://www.who.int/csr/don/2012_07_13/en/.
[4]SolomonT, LewthwaiteP, PereraD, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71[J]. Lancet Infect Dis, 2010, 10(11):778–790.
[5]WHO. A Guide to clinical management and public health response for hand, foot and mouth disease (HFMD)[M]. Manila:WHO Western Pacific Region, 2011:25–30.
[6]KomatsuH, ShimizuY, TakeuchiY, et al. Outbreak of severe neurologic involvement associated with enterovirus 71 infection[J]. Pediatr Neurol, 1999, 20(1):17–23.
[7]HoM, ChenER, HsuKH, et al. An epidemic of enterovirus 71 infection in Taiwan[J]. N Engl J Med, 1999, 341(13):929–935.
[8]OoiMH, WongSC, PodinY, et al. Human enterovirus 71 disease in Sarawak, Malaysia:a prospective clinical, virological, and molecular epidemiological study[J]. Clin Infect Dis, 2007, 44(5):646–656.
[9]ChanKP, GohKT, ChongCY, et al. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore[J]. Emerg Infect Dis, 2003, 9(1):78–85.
[10]秦玉君, 张建军, 张静, 等. 山东省烟台市1398例手足口病患者经济负担及就诊情况调查 [J]. 中华流行病学杂志, 2009, 30(12):1319–1320.
[11]贺天锋, 杨天池, 易波, 等. 宁波市2011年手足口病经济负担估计[J]. 上海预防医学, 2012, 24(9):476–478.
[12]刘涛. 山东省手足口病患者疾病经济负担及影响因素研究[D]. 济南:山东大学, 2013.
[13]XingW, LiaoQ, ViboudC, et al. Hand, foot, and mouth disease in China, 2008–12:an epidemiological study[J]. Lancet Infect Dis, 2014, 14(4):308–318.
[14]WuCN, LinYC, FannC, et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus[J]. Vaccine, 2001, 20(5–6):895–904.
[15]ChungYC, HoMS, WuJC, et al. Immunization with virus–like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge[J]. Vaccine, 2008, 26(15):1855–1862.
[16]YuCK, ChenCC, ChenCL, et al. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice[J]. J Biomed Sci, 2000, 7(6):523–528.
[17]WangLC, KaoCM, LingP, et al. CD4 T–cell–independent antibody response reduces enterovirus 71 lethality in mice by decreasing tissue viral loads[J]. Clin Dev Immoul, 2012 (2012):580696.
[18]LeeMS, ChangLY. Development of enterovirus 71 vaccines[J]. Expert Rev Vaccines, 2010, 9(2):149–156.
[19]WuSC, LiuCC, LianWC. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development[J]. Vaccine, 2004, 22(29/30):3858–3864.
[20]TungWS, BakarSA, SekawiZ, et al. DNA vaccine constructs against enterovirus 71 elicit immune response in mice[J]. Genet Vaccines Ther, 2007, 5(6):1–13.
[21]ChenHF, ChangMH, ChiangBL, et al. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71[J]. Vaccine, 2006, 24(15):2944–2951.
[22]ChiuCH, ChuC, HeCC, et al. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71[J]. Microbes Infect, 2006, 8(7):1671–1678.
[23]AritaM, NagataN, IwataN, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys[J]. J Virol, 2007, 81(17):9386–9395.
[24]FooDG, AlonsoS, PhoonMC, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides[J]. Virus Res, 2007, 125(1):61–68.
[25]ZhangD, LuJ, LuJ. Enterovirus 71 vaccine: close but still far[J]. Int J Infect Dis, 2010, 14(9):e739–e743.
[26]XuJ, QianY, WangS, et al. EV71:an emerging infectious disease vaccine target in the Far East?[J]. Vaccine, 2010, 28(20):3516–3521.
[27]潘浩, 朱叶飞, 祁贤, 等. 江苏省2008年某福利院手足口病暴发的流行病学和病原学特征研究[J]. 中华流行病学杂志, 2009, 30(4):339–343.
[28]Sutton–HayesS, WeisseME, WilsonNW, et al. A recurrent presentation of hand, foot, and mouth disease[J]. Clin Pediatr, 2006, 45(4):373–376.
[29]ChangLY, KingCC, HsuKH, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan[J]. Pediatrics, 2002, 109(6):e88.
[30]LuoST, ChiangPS, ChaoAS, et al. Enterovirus 71 maternal antibodies in infants, Taiwan[J]. Emerg Infect Dis, 2009, 15(4):581–584.
[31]MaoQY, LiaoXY, YuX, et al. Dynamic change of mother–source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants[J]. Chin Med J (Engl), 2010, 123(13):1679–1684.
[32]OoiEE, PhoonMC, IshakB, et al. Seroepidemiology of human enterovirus 71, Singapore[J]. Emerg Infect Dis, 2002, 8(9):995–997.
[33]RabenauHF, RichterM, DoerrHW. Hand, foot and mouth disease:seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany[J]. Med Microbiol Immunol, 2010, 199(1):45–51.
[34]ZhuZ, ZhuS, GuoX, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large–scale outbreaks from 2008[J]. Virol J, 2010, 7(1):300–305.
[35]JiH, LiL, LiuY, et al. Seroepidemiology of human enterovirus71 and coxsackievirusA16 in Jiangsu province, China[J]. Virol J, 2012, 9:248.
[36]LiW, YiL, SuJ, et al. Seroepidemiology of human enterovirus71 and coxsackievirusA16 among children in Guangdong province, China[J]. BMC Infect Dis, 2013, 13(1):322.
[37]ZhuFC, LiangZL, MengFY, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants[J]. PloS One, 2012, 7(5):e37206.
[38]高远征, 贾素华, 李翠萍, 等. 抗–EV71 阳性血浆治疗重症手足口病的临床观察[J]. 中华实验和临床感染病杂志 (电子版), 2012, 6(6):84–87.
[39]SolomonT, LewthwaiteP, PereraD, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71[J]. Lancet Infect Dis, 2010, 10(11):778–790.
[40]ZhangY, TanX, CuiA, et al. Complete genome analysis of the c4 subgenotype strains of enterovirus 71:predominant recombination c4 viruses persistently circulating in china for 14 years[J]. PloS One, 2013, 8(2):e56341.
[41]TanX, HuangX, ZhuS, et al. The persistent circulation of enterovirus 71 in People′s Republic of China:causing emerging nationwide epidemics since 2008. PLoS One, 2011, 6(9):e25662.
[42]WangJR, TuanYC, TsaiHP, et al. Change of major genotype of enterovirus 71 in outbreaks of hand–foot–and–mouth disease in Taiwan between 1998 and 2000[J]. J Clin Microbiol, 2002, 40(1):10–15.
[43]HuangYP, LinTL, KuoCY, et al. The circulation of subgenogroups B5 and C5 of enterovirus 71 in Taiwan from 2006 to 2007[J]. Virus Res, 2008, 137(2):206–212.
[44]McMinnP, LindsayK, PereraD, et al. Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia[J]. J Virol, 2001, 75(16):7732–7738.
[45]CardosaMJ, PereraD, BrownBA, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia–Pacific region:comparative analysis of the VP1 and VP4 genes[J]. Emerg Infect Dis, 2003, 9(4):461–468.
[46]DongC, LiuL, ZhaoH, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys[J]. Vaccine, 2011, 29(37):6269–6275.
[47]MaoQ, ChengT, ZhuF, et al. The Cross–Neutralizing Activity of Enterovirus 71 Subgenotype C4 Vaccines in Healthy Chinese Infants and Children[J]. PloS One, 2013, 8(11):e79599.
[48]ChouAH, LiuCC, ChangJY, et al. Formalin–Inactivated EV71 Vaccine Candidate Induced Cross–Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers[J]. PloS One, 2013, 8(11):e79783.
[49]ZhuFC, LiangZL, LiXL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants:a randomised, double–blind, placebo–controlled phase 2 clinical trial[J]. Lancet, 2013, 381(9871):1037–1045.
[50]ZhuFC, MengFY, LiJX, et al. Efficacy, safety, and immunology of an inactivated alum–adjuvant enterovirus 71 vaccine in children in China:a multicentre, randomised, double–blind, placebo–controlled, phase 3 trial[J]. Lancet, 2013, 381(9882):2024–2032.
[51]ZhuFC, XuWB, XiaJL, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China[J]. N Engl J Med, 2014, 370(9):818–828.
[52]LiR, LiuL, MoZ, et al. An inactivated enterovirus 71 vaccine in healthy children[J]. N Engl J Med, 2014, 370(9):829–837.
[53]LiYP, LiangZL, XiaJL, et al. Immunogenicity, Safety, and Immune Persistence of a Novel Inactivated Human Enterovirus 71 Vaccine:A Phase Ⅱ, Randomized, Double–Blind, Placebo–Controlled Trial[J]. J Infect Dis, 2014, 209(1):46–55.
[54]MengFY, LiJX, LiXL, et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children:an open label, phase 1 clinical trial[J]. Hum Vaccin Immunother, 2012, 8(5):668–674.
[55]LiYP, LiangZL, GaoQ, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine:a randomized, placebo–controlled, double–blind, Phase I clinical trial[J]. Vaccine, 2012, 30(22):3295–3303.
[56]ZhuFC, WangJZ, LiXL, et al. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in chinese healthy children and infants[J]. Pediatr Infect Dis J, 2012, 31(11):1158–1165.
[57]ChengA, FungCP, LiuCC, et al. A Phase I, randomized, open–label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine[J]. Vaccine, 2013, 31(20):2471–2476.
[58]ClemensR, SafaryA, HepburnA, et al. Clinical experience with an inactivated hepatitis A vaccine[J]. J Infect Dis, 1995, 171(Suppl 1):S44–S49.
[59]FadenH. Poliovirus vaccination:a trilogy[J]. J Infect Dis, 1993, 168(1):25–28.
[60]TreanorJJ, CampbellJD, ZangwillKM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine[J]. N Engl J Med, 2006, 354(13):1343–1351.
[61]ShenyuW, JingxinL, ZhenglunL, et al. A booster dose of an inactivated enterovirus 71 vaccine in Chinese young children:a randomized, double–blind, placebo–controlled clinical trial[J]. J Infect Diseases, 2014, In press.
[62]RobertsonSE, DruckerJA, Fabre–TesteB, et al. Clinical efficacy of a new, enhanced–potency, inactivated poliovirus vaccine[J]. Lancet, 1988, 331(8591):897–899.
[63]World Health Organization.Immunological basis for immunization/module 6:poliomyelitis[R]. Geneva:WHO, 1993.
[64]HuangYP, LinTL, HsuLC, et al. Genetic diversity and C2–like subgenogroup strains of enterovirus 71, Taiwan, 2008[J]. Virol J, 2010, 7(277):277.
[65]World Health Organization.Vaccine introduction guidelines.Adding a vaccine to a national immunization programme:decision and implementation[EB/OL]. [2014–04–20]. http://apps.who.int/iris/bitstream/10665/69179/1/WHO_IVB_05.18.pdf?ua=1.
[66]FujimotoT, ⅡzukaS, EnomotoM, et al. Hand, foot, and mouth disease caused by coxsackievirus A6, Japan, 2011[J]. Emerg Infect Dis, 2012, 18(2):337–339.
[67]FlettK, YoungsterI, HuangJ, et al. Hand, foot, and mouth disease caused by coxsackievirus A6[J]. Emerg Infect Dis, 2012, 18(10):1702–1704.

用户评论 0条

用户名: 密码: 登陆 注册
 
  • 9
  • 3
  •  4 : 页次:0/0页 共0条记录 5条/每页
    关于我们 | 专家风采 | 会员注册 | 继续教育
    地 址:北京市西城区东河沿街69号正弘大厦511室 邮 编:100052
    电话:010-51322302
    版权所有 中华医学会及中华预防医学杂志编辑部
    京ICP备 07035254 号